These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 24633813)
1. Mitochondrial membrane fluidity is consistently increased in different models of Huntington disease: restorative effects of olesoxime. Eckmann J; Clemens LE; Eckert SH; Hagl S; Yu-Taeger L; Bordet T; Pruss RM; Muller WE; Leuner K; Nguyen HP; Eckert GP Mol Neurobiol; 2014 Aug; 50(1):107-18. PubMed ID: 24633813 [TBL] [Abstract][Full Text] [Related]
2. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331 [TBL] [Abstract][Full Text] [Related]
3. Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology. Choudhury KR; Das S; Bhattacharyya NP J Proteomics; 2016 Jan; 132():155-66. PubMed ID: 26581643 [TBL] [Abstract][Full Text] [Related]
4. Olesoxime improves cerebral mitochondrial dysfunction and enhances Aβ levels in preclinical models of Alzheimer's disease. Eckert GP; Eckert SH; Eckmann J; Hagl S; Muller WE; Friedland K Exp Neurol; 2020 Jul; 329():113286. PubMed ID: 32199815 [TBL] [Abstract][Full Text] [Related]
5. Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. Jin YN; Yu YV; Gundemir S; Jo C; Cui M; Tieu K; Johnson GV PLoS One; 2013; 8(3):e57932. PubMed ID: 23469253 [TBL] [Abstract][Full Text] [Related]
6. Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate. Weber JJ; Clemensson LE; Schiöth HB; Nguyen HP Biochem Pharmacol; 2019 Oct; 168():305-318. PubMed ID: 31283931 [TBL] [Abstract][Full Text] [Related]
7. Mitochondrial modulators improve lipid composition and attenuate memory deficits in experimental model of Huntington's disease. Mehrotra A; Sood A; Sandhir R Mol Cell Biochem; 2015 Dec; 410(1-2):281-92. PubMed ID: 26374445 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-124 targets CCNA2 and regulates cell cycle in STHdh(Q111)/Hdh(Q111) cells. Das E; Jana NR; Bhattacharyya NP Biochem Biophys Res Commun; 2013 Jul; 437(2):217-24. PubMed ID: 23796713 [TBL] [Abstract][Full Text] [Related]
10. Metabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPARγ. Jin YN; Hwang WY; Jo C; Johnson GV PLoS One; 2012; 7(1):e30406. PubMed ID: 22276192 [TBL] [Abstract][Full Text] [Related]
11. Delayed Cell Cycle Progression in STHdh(Q111)/Hdh(Q111) Cells, a Cell Model for Huntington's Disease Mediated by microRNA-19a, microRNA-146a and microRNA-432. Das E; Jana NR; Bhattacharyya NP Microrna; 2015; 4(2):86-100. PubMed ID: 26165466 [TBL] [Abstract][Full Text] [Related]
12. Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model. Cong WN; Chadwick W; Wang R; Daimon CM; Cai H; Amma J; Wood WH; Becker KG; Martin B; Maudsley S J Biol Chem; 2015 Jan; 290(5):2728-43. PubMed ID: 25505248 [TBL] [Abstract][Full Text] [Related]
13. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. Martin LJ IDrugs; 2010 Aug; 13(8):568-80. PubMed ID: 20721828 [TBL] [Abstract][Full Text] [Related]
14. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. Orr AL; Li S; Wang CE; Li H; Wang J; Rong J; Xu X; Mastroberardino PG; Greenamyre JT; Li XJ J Neurosci; 2008 Mar; 28(11):2783-92. PubMed ID: 18337408 [TBL] [Abstract][Full Text] [Related]
15. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease. Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355 [TBL] [Abstract][Full Text] [Related]
16. The calpain-suppressing effects of olesoxime in Huntington's disease. Weber JJ; Ortiz Rios MM; Riess O; Clemens LE; Nguyen HP Rare Dis; 2016; 4(1):e1153778. PubMed ID: 27141414 [TBL] [Abstract][Full Text] [Related]
17. Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease. Joshi AU; Ebert AE; Haileselassie B; Mochly-Rosen D J Mol Cell Cardiol; 2019 Feb; 127():125-133. PubMed ID: 30550751 [TBL] [Abstract][Full Text] [Related]
18. Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis. Reis SA; Thompson MN; Lee JM; Fossale E; Kim HH; Liao JK; Moskowitz MA; Shaw SY; Dong L; Haggarty SJ; MacDonald ME; Seong IS Hum Mol Genet; 2011 Jun; 20(12):2344-55. PubMed ID: 21447599 [TBL] [Abstract][Full Text] [Related]
19. RTP801 Is Involved in Mutant Huntingtin-Induced Cell Death. Martín-Flores N; Romaní-Aumedes J; Rué L; Canal M; Sanders P; Straccia M; Allen ND; Alberch J; Canals JM; Pérez-Navarro E; Malagelada C Mol Neurobiol; 2016 Jul; 53(5):2857-2868. PubMed ID: 25876513 [TBL] [Abstract][Full Text] [Related]